July #125 : Sneak Previews - by Laura Whitehorn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents

Barely Legal

Speaking of Sex...

La Cage Air Force


Mouthing Off

Skeleton Key

Sneak Previews

The Big Queasy

Measurements, Please

Mass Coverage

Converse All Star

Trainer’s Bench-July 2006

Get Back

The Hunger

Preaching to the Seroconverted

Dead Men Walking

Meth Madness

Buzz Kill

Accounting 101

Kindle Kids

The Keys to Uganda

Under the Counter

Positive Bling

Editor's Letter-July 2006

Mailbox-July 2006

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

email print

July 2006

Sneak Previews

by Laura Whitehorn

New treatments for HIV and its side effects

The first all-in-one HIV combo, mixing Viread (tenofovir), Emtriva (emtricitabine) and Sustiva (efavirenz) in a single once-a-day pill, filed for FDA approval in April and could hit pharmacies any day. It’s already delivered a new marketing term—single-tablet regimen, or STR: It stuffs an entire HIV combo into one tablet. Two companies, Gilead Sciences (maker of Viread and Emtriva) and Bristol-Myers Squibb (Sustiva’s manufacturer), teamed up to parent the triplet. To get it to other parts of the globe, Gilead will need to work with Merck, which sells efavirenz as Stocrin in some countries. All three drugs remain available separately; Viread and Emtriva also appear together as Truvada.

Bio-Alcamid, a filler to fix the facial wasting damage caused by some HIV meds, has been approved in Canada. Unlike Sculptra (the only HIV facial wasting remedy approved in the U.S.), Bio-Alcamid isn’t temporary and usually doesn’t need reapplication. The synthetic gel, injected under the skin with local anesthesia, has been available in Europe and Mexico for several years. Until it’s approved here (the maker predicts a mid-2007 U.S. clinical trial), folks can get treated up north with a doctor’s referral.

A patient-assistance program to help pay the cost (about $3,500 to $4,500, according to a company rep) is available to U.S. as well as Canadian residents; check www.faceforward.ca.  

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.